why choose us

First received: July 06, 2023

Clinical Trial: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Treatment Resistant Schizophrenia

Study Type: INTERVENTIONAL


Official Title: Dextromethorphan as an Augmentation Agent in Treatment-resistant Schizophrenia: A Randomized, Group Sequential Adaptive Design, Controlled Clinical Trial

Brief Summary: Dextromethorphan acts as N-methyl-D-aspartate (NMDA) antagonist.In Treatment resistant schizophrenia(TRS) the efficacy of treatment response by clozapine is only around 40%.Numerous augmentation agent have been tried which includes antipsychotics, anticonvulsants, antidepressants and NMDA antagonist.The NMDA antagonist such as Riluzole and Memantine have shown good efficacy in TRS.Therefore we are evaluating NMDA antagonist, dextromethorphan in TRS.The dextromethorphan or placebo will be administered along with…

Read more